SLM6 is an inhibitor of cyclin-dependent kinase-9 (CDK9). It exhibits potent anti-multiple myeloma activity. References: Dolloff NG, Allen JE, Dicker DT, Aqui N, Vogl D, Malysz J, Talamo G, El-Deiry WS. Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther. 2012 Nov;11(11):2321-30. doi: 10.1158/1535-7163.MCT-12-0578. Epub 2012 Sep 10. PubMed PMID: 22964485; PubMed Central PMCID: PMC3502072.

纯度：≥98%

CAS：22242-91-7